Browse

Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids

Cited 30 time in Web of Science Cited 33 time in Scopus
Authors
Kim, Tae-Wan; Kim, Mi-Na; Kwon, Jae-Woo; Kim, Kyung-Mook; Kim, Won; Chang, Yoon-Seok; Min, Kyung-Up; Kim, You-Young; Cho, Sang-Heon; Park, Heung-Woo; Kim, Sae-Hoon
Issue Date
2010-10
Publisher
WILEY-BLACKWELL
Citation
RESPIROLOGY; Vol.15 7; 1092-1097
Keywords
asthmachronic obstructive pulmonary diseasesystemic corticosteroidinhaled corticosteroidhepatitis B virus reactivation
Abstract
Background and objective: Reactivation of hepatitis B virus (HBV) is thought to be associated with immunosuppressive treatments, but insufficient information is available on the effect of corticosteroids. The aim of this study was to evaluate the risk of HBV reactivation in hepatitis B surface antigen-seropositive patients with asthma or COPD, who were treated with systemic corticosteroids (SCS) in addition to inhaled corticosteroids (ICS). Methods: Patients with asthma or COPD (n = 198), who were hepatitis B surface antigen-seropositive and had been treated with ICS, were identified retrospectively. To evaluate the additional effects of SCS, the SCS group was divided into those who received intermittent or continuous SCS (>= 3 months of continuous SCS treatment), and into those who received low-dose (<= 20 mg/day of prednisolone) or medium-to-high-dose SCS. The study outcome was HBV reactivation. Results: HBV reactivation occurred in 11.1% of patients in the SCS group, which was significantly higher than the reactivation rate in the ICS group. HBV reactivation was more frequent in the SCS group compared with the ICS group (OR 3.813, 95% CI: 1.106-13.145, P = 0.032), and in the continuous and medium-to-high-dose SCS subgroups compared with the ICS group (OR 5.719, 95% CI: 1.172-27.905, P = 0.048 and OR 4.884, 95% CI: 1.362-17.511, P = 0.014, respectively). Conclusions: These results suggest that addition of SCS to ICS increases the risk of HBV reactivation, especially when SCS are administered chronically or at high doses.
ISSN
1323-7799
Language
English
URI
http://hdl.handle.net/10371/77587
DOI
https://doi.org/10.1111/j.1440-1843.2010.01798.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse